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ABSTRACT 
Objective: The present paper reports the development of simple, rapid, accurate and stability indicating reversed phase high-performance liquid 
chromatography method (RP-HPLC) for estimation of related substances in Atorvastatin calcium (ATV) bulk drug as well as in solid dosage form. 
The method was validated using Agela, Unisol C18 (250 mmX 4.6 mm; 5µ) column. 
Methods: A method was developed to separate clearly the drug peak from the synthetic/process impurities and degradation products formed 
under stress conditions is attained on (T/%B) were set at 0/43, 18/43, 20/60, 33/60, 35/43, and 40/43 of 0.02 mM ammonium acetate buffer of 
pH4.9 was used as mobile phase A and 90:10 v/v, ratio of acetonitrile and tetrahydrofuran was used as mobile phase B. A flow rate of 1.4 ml/min 
and column temperature of 25 °C was used. The wavelength selected was 246 nm. The developed method was validated as per ICH guidelines for 
the specificity, precision, linearity, accuracy, limit of detection, limit of quantitation and robustness. 
Results: Linearity of the impurities was accomplished in the range 0.3-6.0µg/ml for impurity A (Imp A), B (Imp B), C (Imp C), H (Imp H) and 0.4-
6.0µg/ml for impurity D (Imp-D), correlation coefficient was found to be more than 0.999 for all impurities. Recovery of impurities was found to be 
in the range 93%-111%. 
Conclusion: The developed method was simple, precise, accurate, robust and also cost effective as it has shorter run time for quantification of 
impurities in drug substance and drug product as well. 
Keywords: Atorvastatin calcium, Impurities, ICH guidelines, Method development, Analytical method validation, Degradation. 
 
INTRODUCTION 
ATV is a synthetic hydroxymethyl glutaryl coenzyme A (HMG-CoA) 
reductase inhibitor that has been demonstrated to be efficacious in 
reducing both cholesterol and triglycerides. It is administered as the 
calcium salt of the active hydroxy acid and is used between 10 and 
80 mg per day to reduce the raised lipid levels in patients with 
primary hyperlipidemia (familial and non-familial) or combine 
hyperlipidemia [1]. As per the literature available, five impurities 
reported in drug substance (refer table 1) named as Imp A, B, C, D, 
and H [2] and for pharmaceuticals, there is no compendia method 
available either in the United States Pharmacopoeia (USP) and 
European Pharmacopoeia (EP). So far many methods are available 
for quantification of impurities, but the current developed method 
has a shorter runtime, which was obtained by using a gradient 
program ensuring that all the impurities elute out efficiently. The 
aim of the study is to develop a simple, reliable and accurate stability 
indicating a method for the determination of ATV and its process 
and also storage related impurities. This manuscript provides a 
detailed procedure for the determination of relative response 
factors (RRF) for the quantitative determination of impurities. 
MATERIALS AND METHODS 
Chemicals and reagents 
Working standard of ATV and five impurities namely Imp A, Imp B, 
Imp C, Imp D, and Imp H were taken from the Ashland analytical lab, 
Hyderabad, Telangana, India. All reagents used were of analytical 
reagent grade. HPLC grade acetonitrile, tetrahydrofuran, and acetic 
acid used from Merck (Darmstadt, Germany). Ammonium acetate 
was from Merck (Darmstadt, Germany). Milli-Q water of high purity 
and filter through 0.22 µm from millipore water system was used. 
Instrument 
A Waters alliance HPLC System e2695 equipped with a PDA detector 
and a quaternary gradient pump was used for the study. All the data 
was acquired using empower 3 data acquisition and integration 
software. Agilent 8453 ultraviolet, visible spectrophotometer was 
used for recording the spectrum. 
Methods 
Method development and optimization 
Four experiments were conducted using sample solution containing 
ATV and its impurities at the specified concentration (refer table 2) 
[3] and injected onto the HPLC in order to obtain a better separation 
in a shorter run time. 
Experiment 1 
Initially, solutions containing 0.8 mg/ml of ATV, 0.004 mg/ml of all 
impurities, placebo equivalent to one tablet was prepared and 
injected onto RP-HPLC equipped with Agilent Zorbax Rx-C8 column 
of dimension 250 mm X 4.6 mm i. d, 5µ particle size. A mixture of 
acetonitrile, tetrahydrofuran, and buffer (3.9 g/l of ammonium 
acetate in water, adjusted to pH 5.0 with glacial acetic acid) in the 
ratio of 21:12:67 and 61:12:27 v/v/v were used as mobile phase A 
and B respectively. 
Experiment 2 
The column temperature was maintained at 35 
°C and the flow rate was 1.5 ml/min. A gradient program (T/%B) 
was set at 0/0, 40/0, 70/80, 85/100, 100/100, 105/0, and 115/0. 
The detector wavelength was 246 nm. 
In order to overcome the difficulties in the experiment 1, the column 
was replaced with Phenominex Luna C18, 250 mm x 4.6 mm i. d, 5µ 
particle size. And different combinations of buffer (1.5 g/l 
of ammonium acetate in water, adjusted with glacial acetic acid to a 
pH of 4.45) acetonitrile and tetrahydrofuran were used. The flow 
rate was 1.0 ml/min, column oven temperature was 35 °C and 
the gradient program (T/%B) was set at 0/20, 15/26, 45/35, 75/65, 
80/20, and 90/20. 
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Experiment 3 
Here, Waters X-Bridge column having dimensions 50 mm x 4.6 
mm i. d, 3.5 µ particle size was used to decrease the analysis 
time, considering the same mobile phase A and B as in 
experiment 2. Different combination of buffer, acetonitrile, and 
tetrahydrofuran were used to optimize the method. The flow 
rate was 1.4 ml/min and the column temperature was at 25 °C. 
The 
Experiment 4 
gradient program (T/%B) was set at 0/20, 15/20, 20/35, 
22/20, and 30/20. 
Here, Agela, Unisol C18 column having dimensions of 250 mm x 4.6 
mm i. d, 5 µ particle size was used. 0.02 M ammonium acetate buffer 
adjusted to pH 4.9 was used as mobile phase A, different 
combination mixtures of acetonitrile, tetrahydrofuran were used 
and finally the ratio of 90:10 v/v, was set as mobile phase B. The 
gradient program (T/%B) was set at 0/43, 18/43, 20/60, 33/60, 
35/43, and 40/43. The flow rate was 1.4 ml/min and the column 
temperature was at 25 °C. The detector wavelength was 246 nm. 
  




[(3R,5R)-7-[3-(Phenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium 
salt] 
 Imp A 
 
(3R, 5R)-7-[3-(phenylcarbamoyl)-2-isopropyl-4,5-diphenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid calcium salt) 
Imp B 
 
(3S,5R)-7-[3-(phenylcarbomoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1Hpyrrol-1-yl]-3,5-dihyroxyheptanoicacid, calcium salt. 
Imp C 
 
(3R,5R)-7 [3-(phenylcarbomoyl)-4,5-bis(4-fluorophenyl)-2-isopropyl-1H-pyrrol-1-yl]-3,5-dihyroxyheptanoicacid, sodium salt. 
Imp D 
 
ATV epoxide impurity OR 3-(4-fluorophenyl)-2-isobutyryl-3-phenyloxirane-2-carboxylic acid phenylamide 





Table 2: Concentration of ATV and its impurities 
Compound Concentration 
mg/ml µg/ml 
ATV 0.8 800 
ATV impurities 0.004 4 
Unknown concentration 0.0016 1.6 
 
RESULTS AND DISCUSSION 
Method development 
Experiment 1 
Here, separation of all the peaks was observed, but the baseline 
fluctuations were more and also total run time was kept long for elution 
of all the impurities. Representative chromatogram is shown in fig. 1. 
Experiment 2 
Here, the baseline fluctuation was observed to be less as compared 
to experiment 1.  
However, HPLC run time was still longer and could not be shortened 
due to elution of all the peaks. Representative chromatogram is 
shown in fig. 2. 
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Experiment 3 
Here, one of the impurity named as Imp B was not seen, as it 
probably merged with the main peak, since peak purity was out of 
the range for ATV peak and resolution between ATV and Imp C was 
found to be lesser than 1.5, this experiment did not work, since it 
was not meeting the system suitability criteria. Representative 
chromatogram is shown in fig. 3. 
 
Fig. 1: Typical chromatogram of ATV and its impurities from experiment 1 
 
 
Fig. 2: Typical chromatogram of ATV and its impurities from experiment 2 
 
 
Fig. 3: Typical chromatogram of ATV and its impurities from experiment 3 
 
 
Fig. 4: Typical chromatogram of ATV and its impurities from experiment 1 
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Imp-B is one of the isomers of ATV, and its peak separation was not 
seen even on a shorter column used in RP-HPLC.  
Here in this experiment Agela, Unisol C18 column was considered, 
due to its properties of high carbon loading (18%). Assuming that all 
the impurities can retain well on this column as compared with the 
previous columns, this was chosen. A representative chromatogram 
is shown in fig. 4. 
Here, it was observed that all the peaks got separated with good 
peak shapes. And also the run time was very short, it has reduced 
almost three times as compared to the run times available in the 
existing literature for ATV molecule. In order to achieve separation 
of five impurities of ATV in a shorter run time and to save time 
chemicals and other sources, different HPLC parameters like buffer 
pH, the ratio of buffer and organic modifier and also the flow rate 
were optimized. The summary of method development is shown in 
table 3. 
 
Table 3: Summary of method optimization 
Experiment Column Observation 
1 Agilent, Zorbax Rx-C8, 250 mm X 4.6 mm i. d, 5µ particle size Longer run time and baseline fluctuations. 
2 Phenominex Luna, C18, 250 mm X 4.6 mm i. d, 5µ particle size Still longer run time and baseline fluctuations. 
3 Waters X Bridge, 50 mm X 4.6 mmi. d, 3.5µ particle size Complete merging of Imp B with ATV main peak. 
4 Agela, Unisol C18, 250 mm X 4.6 mm i. d, 5µ particle size Good separation, baseline and run time are reduced to 40 min. 
 
Robustness 
The robustness of an analytical procedure is a measure of its 
capacity to remain unaffected by small, but deliberate variations in 
method parameters and provides an indication of its reliability 
during normal usage. The robustness is a measure of the capacity of 
a method to remain unaffected by small but deliberate changes by 
varying the parameters like column temperature (±2 °C), flow rate 
(±0.1 ml/min), column (different lot number), pH (±0.1), mobile 
phase B (±10%) of least contribution component (tetrahydrofuran), 
and wavelength (±2 nm). ATV test preparation was prepared by 
spiking with blend impurity solution at release specification level of 
0.5% of ATV test concentration and injected in to the HPLC system. 
The system suitability parameters were evaluated and were found 
to be within the acceptance criteria. The results are tabulated in the 
table 4. 
 
Table 4: Robustness 
Actual condition Changed condition Theoretical 
Plates (N) 
Tailing factor (T) USP resolution between ATV and 
Imp B Imp C 
1.4 ml/min 1.3 ml/min ATV: 10125  
Imp B: 13977 
Imp C: 11754 
ATV: 1.4 
Imp B: 1.0 
Imp C: 1.1 
2.1 2.5 
 1.5 ml/min ATV: 12015 
Imp B: 15218 
Imp C: 14125 
ATV: 1.2 
Imp B: 1.0 
Imp C: 1.0 
1.9 2.3 
246 nm 244 nm ATV: 11075 
Imp B: 15087 
Imp C: 12841 
ATV: 1.3 
Imp B: 1.0 
Imp C: 1.1 
2.0 2.5 
 248 nm ATV: 11084 
Imp B: 15147 
Imp C: 12321 
ATV: 1.3 
Imp B: 1.0 
Imp C: 1.1 
2.0 2.5 
25 °C 23 °C ATV: 989 
Imp B: 12315 
Imp C: 11254 
ATV: 1.3 
Imp B: 1.0 
Imp C: 1.1 
2.0 2.5 
 27 °C ATV: 13154 
Imp B: 15214 
Imp C: 13215 
ATV: 1.2 
Imp B: 1.0 
Imp C: 1.0 
1.9 2.3 
4.9 pH 4.8 pH ATV: 11055 
Imp B: 14987 
Imp C: 12744 
ATV: 1.4 
Imp B: 1.0 
Imp C: 1.1 
1.7 2.1 
 5.0 pH ATV: 11055 
Imp B: 14987 
Imp C: 12744 
ATV: 1.3 
Imp B: 1.0 
Imp C: 1.1 
1.9 2.1 
100 ml THF in 1000 ml of mobile phase B 90 ml ATV: 12015 
Imp B: 15287 
Imp C: 13748 
ATV: 1.2 
Imp B: 1.0 
Imp C: 1.1 
1.8 2.1 
110 ml ATV: 10125 
Imp B: 12587 
Imp C: 12144 
ATV: 1.3 
Imp B: 1.0 
Imp C: 1.1 
2.0 2.3 
Column change Column 1 
Lot# AQ-110523 
ATV: 11055 
Imp B: 14987 
Imp C: 12744 
ATV: 1.3 
Imp B: 1.0 





Imp B: 15014 
Imp C: 13015 
ATV: 1.3 
Imp B: 1.0 
Imp C: 1.1 
2.0 2.5 
Here it was observed that by varying the above parameters, much impact was not shown on the resolution, tailing factor, theoretical plates, and 
relative retention times of ATV impurities. Hence, the method was found to be robust. 
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System suitability solution 
The system suitability test is a critical parameter for an analysis as it 
evaluates both the instrument and method performance. The sample 
solution containing ATV spiked with Imp B and Imp C at the 
specification level with respect to the sample concentration were 
injected onto the HPLC system.  
The representative chromatogram is shown in fig. 5 and the system 
suitability test results are tabulated in table 5. 
 
 
Fig. 5: System suitability solution chromatogram 
 
Table 5: System suitability parameters 
Parameter Specification Results 
Theoretical plates (N) ≥ 2000 ATV: 11055 
Imp B: 14987 
Imp C: 12744 
Tailing factor (T) ≤ 1.5 ATV: 1.3 
Imp B: 1.0 
Imp C: 1.1 
Resolution between 
Imp B and ATV (R) 
≥ 1.5 2.0 
Resolution between 
ATV and Imp C (R) 
≥ 1.5 2.5 
 
Analytical method validation 
The objective of validation of an analytical procedure is to prove that 
it is suited for its designated use. The proposed method has been 
validated for the related substances as per ICH guidelines [6]. 
Relative response factors determination 
Relative response factors were calculated by injecting all the 
impurities and ATV as an unknown from 0.5 to 6 ppm concentration 
onto the HPLC system. The relative response factor (RRF) of each 
impurity was determined by dividing the slope of each impurity by 
the slope of ATV calcium from the linearity curve. The relative 
response factors and relative retention times for individual 
impurities are tabulated in table 6. 
Validation parameters 
• Specificity  
• Precision  
 Repeatability  
 Intermediate Precision  
 Reproducibility 
• Detection and Quantization Limit 
• Linearity  
• Accuracy  
• Range 
Specificity 
Specificity is the ability to assess the analyte unequivocally in the 
presence of components, which might include impurities, 
degradants and matrix. Specificity was performed in terms of forced 
degradation. 
Degradation study 
Stress testing of the drug substance can help identify the likely 
degradation products, which can in turn help establish the 
degradation pathways and the intrinsic stability of the molecule and 
also validate the stability indicating the power of the analytical 
procedures used [4, 5]. 
 
Table 6: Relative response factors and relative retention times 
Compound name Relative retention time Relative response factor 
ATV 1.00 1.00 
Imp A 0.86 1.01 
Imp B 0.94 0.89 
Imp C 1.10 0.87 
Imp D 2.53 0.63 
Imp H 1.98 0.96 
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Fig. 6: Overlaid chromatograms of placebo and ATV with Imp A, B, C, D, and H 
 
Conditions for degradation 
Hydrolytic condition 
Hydrolysis is one of the most common degradation chemical 
reactions over a wide range of pH. Hydrolytic study under acidic, 
basic and neutral condition involves catalyzation of ionizable 
functional groups present in the molecule. Here the sample was 
refluxed with 2N HCL/2N NaOH/Water at 60 °C for 5 h. The 
representative chromatograms are shown in fig. 7-9. 
Oxidative condition 
Generally, most of the samples undergo auto-oxidation under 
atmospheric oxygen conditions. Auto-oxidation is a free radical 
reaction that involves a free radical initiator to start out the chain 
reaction and here hydrogen peroxide act as an initiator for the same. 
Here the sample was oxidized using 3% hydrogen peroxide at a 
temperature not exceeding 60 ˚C for 2 h. The representative 
chromatogram is shown in fig. 10. 
Thermal condition 
In general, the rate of a reaction increases with an increase in 
temperature. Hence, the drugs are susceptible to degradation at a 
higher temperature. Here the sample was kept at 105˚C for about 48 
h. The representative chromatogram is shown in fig. 11. 
Photolytic condition 
Exposure of drug molecules to light may produce degraded 
photolytic products. The rate of photo degradation depends upon 
the intensity of incident light and quantity of light absorbed by the 
drug molecule. Photolytic degradation is carried out by exposing the 
drug product with a combination of visible and UV light. Here the 
sample tablet powder was exposed to ultraviolet radiation up to a 
lower limit of 200-watt h/m2
Humidity condition 
 and a lower limit of 1.2 million lux 
hours of visible light in the photostability chamber. The 
representative chromatogram is shown in fig. 12. 
Humidity is the key factor in establishing the potential degradants in 
the finished product and active pharmaceutical ingredient. Here the 
sample was exposed at 90% humidity for one week. The 
representative chromatogram was shown in fig. 13. 
The mass balance of all the conditions was found to be more than 
99.2%. The Purity angle was found to be less than purity threshold 
and also no purity flag is present (refer table 7). 
  
Table 7: Degradation results 
Condition % net degradation Purity angle Purity  threshold Purity flag (yes/no) 
Unstressed 0.52 0.033 0.263 No 
Acid stressed 9.32 0.023 0.256 No 
Water 0.90 0.036 0.263 No 
Base stressed 0.52 0.029 0.261 No 
Peroxide stressed 19.1 0.034 0.260 No 
Photolytic stressed 0.54 0.029 0.263 No 
Sunlight stressed 0.55 0.032 0.261 No 
Thermal stressed 2.22 0.027 0.261 No 
Humidity 0.58 0.028 0.259 No 
 
 
Fig. 7: Chromatogram represents acidic condition 
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Fig. 8: Chromatogram represents basic condition 
 
 
Fig. 9: Chromatogram represents water condition 
 
 
Fig. 10: Chromatogram represents oxidative condition 
 
 
Fig. 11: Chromatogram represents thermal condition 
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Fig. 12: Chromatogram represents photolytic condition 
 
 
Fig. 13: Chromatogram represents humidity condition 
 
Method precision: repeatability 
Repeatability expresses the precision under the same operating 
conditions over a short interval of time. Repeatability is also termed 
as intra-assay precision. The Precision of test method was evaluated 
by injecting six samples prepared by spiking test preparation with 
ATV impurities solution to get concentration at release specification 
level of 0.5% of Imp A, B, C, D, and H of ATV test concentration. The 
% relative standard deviation was found in between 1.5 to 3.5. The 
results are tabulated in table 8. 
 
Table 8: Repeatability 
Name of the 
impurity 
Concentration (%) Average SD % RSD 
Imp A 0.461 0.449 0.442 0.454 0.456 0.467 0.455 0.01 1.9 
Imp B 0.511 0.535 0.483 0.507 0.505 0.523 0.511 0.02 3.5 
Imp C 0.522 0.500 0.505 0.505 0.513 0.512 0.510 0.01 1.5 
Imp D 0.509 0.475 0.485 0.501 0.494 0.464 0.488 0.02 3.4 
Imp H 0.536 0.541 0.525 0.532 0.545 0.547 0.538 0.01 1.6 
 
Intermediate precision (Ruggedness) 
The intermediate Precision was conducted by two different 
analysts, on different days using different columns. Three 
samples were prepared by spiking test preparation with ATV 
impurities solution to get concentration at release specification 
level of 0.5% of ATV test concentration at each condition.  
The % relative standard deviation between all the three conditions 
was found in between 1.3 to 3.0. The results are tabulated in table 9. 
 
Table 9: Intermediate precision 
Name of the 
impurity 











Imp A 0.461 0.449 0.442 0.451 0.462 0.459 0.478 0.477 0.472 0.461 0.01 2.7 
Imp B 0.511 0.535 0.483 0.522 0.522 0.530 0.503 0.512 0.510 0.514 0.02 3.0 
Imp C 0.522 0.500 0.505 0.517 0.515 0.513 0.510 0.508 0.509 0.511 0.01 1.3 
Imp D 0.509 0.476 0.486 0.502 0.506 0.507 0.499 0.502 0.500 0.499 0.01 2.2 
Imp H 0.536 0.541 0.525 0.521 0.530 0.525 0.505 0.510 0.510 0.523 0.01 2.4 
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Limit of detection (LOD) and limit of quantification (LOQ) from 
prediction linearity 
The detection limit of an individual analytical procedure is the 
lowest amount of analyte in a sample which can be detected but not 
necessarily quantitated as an exact value. The quantitation limit of 
an individual analytical procedure is the lowest quantity of analyte 
in a sample which can be quantitatively determined with suitable 
precision and accuracy. 
A study to establish the LOD and LOQ for ATV (as unknown) and its 
related compounds was conducted. The LOD and LOQ was 
established by slope method from lowest level (10%) to 150% of 
target concentration. 
A series of eight dilutions with increasing concentrations were 
injected onto the HPLC system. A graph of concentration vs. area 
was plotted. The LOD and LOQ were calculated based on the 
standard deviation of response and slope (refer table 10). 
 
Table 10: LOD and LOQ 
Compound name LOD, % LOQ, % 
ATV as unknown 0.01 0.04 
Imp A 0.01 0.04 
Imp B 0.01 0.04 
Imp C 0.01 0.04 
Imp D 0.02 0.05 
Imp H 0.01 0.04 
 
Precision and accuracy at LOQ level 
The precision of ATV having its impurities at about the LOQ was 
conducted. Six test preparations of ATV and its impurities at the 
quantification level were prepared and injected onto the HPLC 
system. The % RSD of spiked concentrations for six replicate were 
found between 3.2 to 7.8. The precision of the ATV was spiked at the 
quantification level on placebo equivalent to test concentration and 
were injected onto the HPLC system. The % RSD was found to be 1.5 
(refer table 11). 
The accuracy of ATV having its impurities at about the limit of 
quantification level was conducted. Impurities were spiked at the 
quantification level using ATV drug product equivalent to test 
concentration. Six preparations were prepared and injected onto the 
HPLC system. The % recovery of ATV impurities at the 
quantification were calculated and found to be in between 94 to 108. 
Results are tabulated in the table 11. 
Accuracy of the ATV at Quantification limit was conducted. ATV 
stock was spiked at quantification limit on placebo equivalent to test 
concentration. Six preparations were prepared and injected onto the 
HPLC system. The % recovery of the ATV at the quantification limit 
were calculated and found to be in between 101 to 105. Results are 
tabulated in the table 12. 
 
Table 11: Precision at LOQ 
Name of the 
component 
Concentration (%) Average SD % RSD 
ATV as unknown 0.0382 0.0375 0.0382 0.0386 0.0389 0.0375 0.0382 0.001 1.5 
Imp A 0.0396 0.0414 0.0411 0.0412 0.0389 0.0385 0.0401 0.001 3.2 
Imp B 0.0372 0.0391 0.0371 0.0396 0.0371 0.0361 0.0377 0.001 3.6 
Imp C 0.0369 0.0374 0.0317 0.0352 0.0402 0.0374 0.0365 0.003 7.8 
Imp D 0.0540 0.0566 0.0577 0.0525 0.0521 0.0561 0.0548 0.002 4.2 
Imp H 0.0400 0.0365 0.0355 0.0421 0.0372 0.0372 0.0381 0.002 6.5 
 
Table 12: Accuracy at LOQ 
Name of the 
component 
% Recovery Average SD % RSD 
ATV 103.3 101.4 103.4 104.3 105.2 101.4 103.2 1.5 1.5 
Imp A 103.7 108.5 107.7 107.8 101.8 100.8 105.1 3.4 3.2 
Imp B 98.9 104.0 98.6 105.3 98.7 96.0 100.3 3.6 3.6 
Imp C 101.0 102.6 86.8 96.4 110.1 102.5 99.9 7.8 7.8 
Imp D 106.0 111.0 113.2 103.0 102.3 110.1 107.6 4.5 4.2 
Imp H 98.7 90.0 87.4 103.8 91.7 91.7 93.9 6.1 6.5 
 
Linearity 
The linearity of an analytical procedure is it's ability (within a given 
range) to obtain test results which are directly proportional to the 
concentration (amount) of analyte in the sample. 
Five solutions with concentration ranging from quantification limit 
to 150% of the specification of ATV impurities (0.5% of Imp-A, B, C, 
D, H and 0.2% maximum unknown impurity) were prepared.  
The Linearity was established by plotting a graph of 
concentration versus area response of ATV, impurities and the 
correlation coefficient was determined.  
The linearity of impurities was obtained and the correlation 
coefficient was found to be more than 0.999 for all impurities 
(refer table 13). 
Accuracy 
The accuracy of an analytical procedure expresses the closeness of 
agreement between the value which is accepted either as a 
conventional true value or an accepted reference value and the value 
found.  
The Accuracy study of ATV and its impurities was performed by 
spiking impurities on test preparation. Samples were prepared in 
triplicate by spiking at the levels of 50%, 100%, and 150% to get the 
target concentration of ATV impurities solution [0.5% of ATV test 
concentration (4 ppm)]. 
Accuracy analysis was also performed for ATV by spiking ATV stock 
solution on placebo preparation (equivalent to test concentration) 
with 50%, 100%, and 150% of the target concentration of ATV 
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[target concentration is 0.2% (1.6 ppm)]. Each sample was prepared 
in triplicate by spiking test preparation with respective levels of the 
target impurity concentration. % Recoveries were found in between 
97 to 106 for ATV and its impurities (refer table 14). 
 
Table 13: Linearity 
Name of the 
Component 
Correlation coefficient Slope Intercept Bias at 100% 
ATV as unknown 0.9996 17774 1004 3.6 
Imp A 0.9999 1206 14897 1.9 
Imp B 0.9999 680 14940 1.1 
Imp C 0.9998 1583 14349 2.8 
Imp D 0.9996 1845 10794 4.0 





Fig. 14: Linearity graphs 
 
Table 14: Accuracy 
Name of the 
component 
Mean recovery of 
50% 
Mean recovery of 
100% 
Mean recovery of 
150% 
Average SD % RSD 
(precision) 
ATV as unknown 103.1 105.4 104.2 104.2 1.2 1.1 
Imp A 99.9 99.0 103.7 100.9 2.5 2.5 
Imp B 100.7 101.6 102.3 101.5 0.8 0.8 
Imp C 97.9 99.2 102.1 99.7 2.2 2.2 
Imp D 107.6 110.4 99.5 105.8 5.7 5.3 
Imp H 95.6 97.8 106.5 100.0 5.8 5.8 
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Range 
The range of an analytical procedure is the interval between the 
upper and lower concentration (amounts) of analyte in the sample 
(including those concentrations) for which it has been demonstrated 
that the analytical procedure has a suitable level of precision, 
accuracy and linearity. The overall data of the quantification limit, 
accuracy and linearity were reflecting the range of the method. 
CONCLUSION 
The developed method was validated with respect to linearity, 
precision, accuracy and specificity. The specificity of the method was 
established by performing forced degradation under different stress 
conditions. Hence, this stability indicating method is useful for the 
determination of related substances in ATV bulk drug substance and 
in the dosage form. 
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